DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
⚠️ IMPORTANT NOTICE / AVVISO IMPORTANTE:
This document is a news digest and company profile compiled from publicly available sources (SEC filings, press releases, official company announcements). It is NOT investment advice, NOT a recommendation to buy or sell, and does NOT constitute a solicitation of any kind. The author is NOT a licensed financial advisor. Always conduct your own due diligence and consult a qualified professional before making any financial decisions.
Questo documento è un digest di notizie e profilo aziendale compilato da fonti pubbliche (SEC filing, comunicati stampa, annunci ufficiali). NON è un consiglio di investimento, NON è una raccomandazione di acquisto o vendita, e NON costituisce sollecitazione di alcun tipo. L'autore NON è un consulente finanziario autorizzato. Effettua sempre la tua due diligence e consulta un professionista qualificato prima di prendere decisioni finanziarie.
This document is a news digest and company profile compiled from publicly available sources (SEC filings, press releases, official company announcements). It is NOT investment advice, NOT a recommendation to buy or sell, and does NOT constitute a solicitation of any kind. The author is NOT a licensed financial advisor. Always conduct your own due diligence and consult a qualified professional before making any financial decisions.
Questo documento è un digest di notizie e profilo aziendale compilato da fonti pubbliche (SEC filing, comunicati stampa, annunci ufficiali). NON è un consiglio di investimento, NON è una raccomandazione di acquisto o vendita, e NON costituisce sollecitazione di alcun tipo. L'autore NON è un consulente finanziario autorizzato. Effettua sempre la tua due diligence e consulta un professionista qualificato prima di prendere decisioni finanziarie.
?? English Version
? NRx Pharmaceuticals (NRXP)
Company Profile & News Digest — CNS Biotech: Ketamine & Suicidal Depression
Update: November 26, 2025
? MULTIPLE FDA CATALYSTS Q4 2025
✓ ANDA "No Significant Deficiencies"
✓ Breakthrough Therapy
✓ Fast Track
NASDAQ: NRXP | Price: ~$2.18 | Market Cap: ~$60M | YTD: +162% | 52-Week: $0.82 - $5.80
? NRx Pharmaceuticals (NRXP) — Multi-Catalyst CNS Play: NRX-100, NRX-101, KETAFREE™ FDA Submissions Q4 2025 / H1 2026
? RECENT NEWS HIGHLIGHTS: NRx has three FDA submission pathways converging in Q4 2025:
- Nov 6, 2025: FDA confirms ANDA re-filing has "no significant deficiencies"
- NRX-100 NDA: PDUFA target before Dec 31, 2025
- NRX-101 NDA: Rolling review under Breakthrough Therapy
- KETAFREE™ ANDA: Priority Review requested
Table of Contents
1. Company Overview
NRx Pharmaceuticals is a clinical-stage CNS biotech focused on NMDA receptor-modulating therapeutics for suicidal depression, bipolar disorder, chronic pain, and PTSD. The company has two lead drug candidates in advanced regulatory submissions.
? Key Developments (From Official Sources):
- Three separate regulatory pathways (2 NDAs + 1 ANDA) currently active
- FDA confirmed "no significant deficiencies" on ANDA (Nov 6, 2025)
- NRX-101 has Breakthrough Therapy Designation; NRX-100 has expanded Fast Track
- HOPE clinics generating first revenue ($242K in Q3 2025)
- No FDA-approved treatment for suicidal depression currently exists
2. Pipeline Status
? NRX-100 (Preservative-Free IV Ketamine)
NDA Filing ANDA Filed Fast TrackIndication: Suicidal Ideation in Depression (including Bipolar Depression)
Mechanism: NMDA receptor modulator — rapid-acting antidepressant effect
Key Differentiator: PRESERVATIVE-FREE formulation (eliminates benzethonium chloride)
Regulatory Status (per company filings):
- NDA: Filing in progress; PDUFA target before Dec 31, 2025
- ANDA (KETAFREE™): Re-filed Sept 29, 2025; FDA confirmed "no significant deficiencies" Nov 6, 2025
- Fee Waiver: $4.3M NDA submission fee waived by FDA
? NRX-101 (D-Cycloserine + Lurasidone)
NDA Rolling Review Breakthrough TherapyIndication: Suicidal Treatment-Resistant Bipolar Depression
Mechanism: Oral fixed-dose combination maintaining ketamine's neuroplasticity benefits
Regulatory Status:
- NDA: Module 3 (manufacturing) submitted; rolling review under Breakthrough
- PDUFA: Company targets before year-end 2025
3. FDA Timeline (Official Announcements)
? Nov 6, 2025 — ANDA Status Update
FDA confirmed KETAFREE™ ANDA has "no significant deficiencies"
Source: Company press release. Priority Review requested.
? Q4 2025 — NRX-100 NDA PDUFA
Company states PDUFA target date before December 31, 2025
NDA for preservative-free ketamine. Fast Track designation. $4.3M filing fee waived.
? Q4 2025 — NRX-101 NDA Rolling Review
Breakthrough Therapy designation enables rolling review
Module 3 submitted per company announcement.
? H1 2026 — KETAFREE™ ANDA (Company Target)
Company anticipates potential approval mid-2026
Based on "no significant deficiencies" confirmation.
? 2026+ — HOPE Network Expansion
Ongoing clinic acquisitions announced
ONE-D Protocol launched Nov 10, 2025 (first in Florida).
4. HOPE Therapeutics Subsidiary
NRx operates HOPE Therapeutics, a subsidiary running interventional psychiatry clinics offering ketamine infusions, TMS, Spravato®, and other treatments.
| Milestone | Date | Detail |
|---|---|---|
| Dura Medical Acquisition | Sept 8, 2025 | Naples & Ft. Myers, FL clinics acquired |
| First Revenue | Q3 2025 | $242,000 patient service revenue |
| Cohen & Associates | Oct 2025 | Sarasota FL clinic added |
| ONE-D Protocol Launch | Nov 10, 2025 | Company reports 87% response, 72% remission |
5. Financial Data (SEC Filings Q3 2025)
5.1 Income Statement
| Item ($M) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Patient Service Revenue | $0.24 | $0.00 | $0.24 | $0.00 |
| R&D Expenses | $1.8 | $2.1 | $5.2 | $7.5 |
| SG&A Expenses | $3.5 | $3.0 | $10.4 | $10.1 |
| Net Loss | ($5.7) | ($5.0) | ($28.9) | ($17.3) |
5.2 Balance Sheet (September 30, 2025)
| Item | Sep 30, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash & Equivalents | $7.1M | $5.9M |
| Subscription Receivable | $3.2M | — |
| Total Assets | $15.0M | $9.0M |
| Total Liabilities | $40.8M | $42.9M |
| Stockholders' Deficit | ($25.8M) | ($33.9M) |
| Accumulated Deficit | ($307.3M) | ($278.4M) |
| Shares Outstanding | 27.7M | 14.6M |
6. Target Market Size (Company Estimates)
>$3B
Suicidal Depression
(Company estimate)
(Company estimate)
>$1B
Bipolar Depression
(Company estimate)
(Company estimate)
$750M+
IV Ketamine Market
(Industry estimate)
(Industry estimate)
~48,000
US Suicides/Year
(CDC data)
(CDC data)
7. Risk Factors (From SEC Filings)
The following risks are disclosed in the company's SEC filings:
? Financial Risks
- Going concern warning included in Q3 2025 10-Q
- Negative stockholders' equity of ($25.8M)
- Shares nearly doubled in 2025 (14.6M → 27.7M)
- Significant warrant and convertible note liabilities
- Management states cash runway through Q2 2026 only
? Regulatory Risks
- FDA could request additional data or issue Complete Response Letter
- NDA approvals are not guaranteed even with Breakthrough/Fast Track
- Competitive products (Spravato®, generics) already on market
? Execution Risks
- HOPE clinic integration and scaling requires execution
- Commercial infrastructure for drug launch not yet built
- Competition from established players
8. Possible Outcomes
Based on publicly available information, the following scenarios are theoretically possible. This is NOT a prediction or recommendation.
? Positive Scenario
One or more FDA approvals in Q4 2025 / H1 2026; HOPE revenue scales; no major dilution required.
? Neutral Scenario
FDA requests additional data; approvals delayed; company raises additional capital with some dilution; operations continue.
? Negative Scenario
FDA issues CRL on all submissions; significant dilution or going concern issues materialize.
9. Official Sources & SEC Links
SEC Filings
Press Releases (Official)
Company Resources
?? Versione Italiana
? NRx Pharmaceuticals (NRXP)
Profilo Aziendale & Digest Notizie — CNS Biotech: Ketamina e Depressione Suicidaria
Aggiornamento: 26 Novembre 2025
? MULTIPLI CATALYST FDA Q4 2025
✓ ANDA "Nessuna Deficienza Significativa"
✓ Breakthrough Therapy
NASDAQ: NRXP | Prezzo: ~$2.18 | Market Cap: ~$60M | YTD: +162% | 52-Week: $0.82 - $5.80
? NOTIZIE RECENTI: NRx ha tre percorsi regolatori FDA convergenti in Q4 2025:
- 6 Nov 2025: FDA conferma che l'ANDA re-filed "non ha deficienze significative"
- NRX-100 NDA: PDUFA target entro 31 Dicembre 2025
- NRX-101 NDA: Rolling review sotto Breakthrough Therapy
- KETAFREE™ ANDA: Priority Review richiesta
1. Profilo Aziendale
NRx Pharmaceuticals è una biotech CNS clinical-stage focalizzata su terapie modulatrici del recettore NMDA per depressione suicidaria, disturbo bipolare, dolore cronico e PTSD.
2. Status Pipeline
? NRX-100 (Ketamina IV Senza Conservanti)
NDA Filing ANDA Filed Fast TrackIndicazione: Ideazione Suicidaria nella Depressione
Status: NDA in corso; ANDA confermato "no significant deficiencies" 6 Nov 2025
? NRX-101 (D-Cicloserina + Lurasidone)
NDA Rolling Review Breakthrough TherapyIndicazione: Depressione Bipolare Suicidaria Treatment-Resistant
Status: Module 3 sottomesso; rolling review attivo
3. Timeline FDA (Annunci Ufficiali)
? 6 Nov 2025 — ANDA Status
FDA conferma KETAFREE™ ANDA "no significant deficiencies"
? Q4 2025 — NRX-100 NDA PDUFA
Target entro 31 Dicembre 2025 (da annuncio aziendale)
? Q4 2025 — NRX-101 Rolling Review
Breakthrough Therapy designation attivo
4. Dati Finanziari (SEC Q3 2025)
| Voce | 30 Set 2025 | 31 Dic 2024 |
|---|---|---|
| Cash & Equivalents | $7.1M | $5.9M |
| Totale Attività | $15.0M | $9.0M |
| Totale Passività | $40.8M | $42.9M |
| Deficit Azionisti | ($25.8M) | ($33.9M) |
| Azioni in Circolazione | 27.7M | 14.6M |
5. Fattori di Rischio (Da SEC Filing)
? Rischi Finanziari
- Going concern warning nel 10-Q Q3 2025
- Patrimonio netto negativo di ($25.8M)
- Azioni quasi raddoppiate nel 2025 (14.6M → 27.7M)
- Cash runway dichiarato fino a Q2 2026
? Rischi Regolatori
- FDA potrebbe richiedere dati aggiuntivi o emettere CRL
- Approvazioni NDA non garantite anche con Breakthrough/Fast Track
- Competizione da Spravato® e ketamina generica
6. Possibili Scenari
Basandosi su informazioni pubbliche, i seguenti scenari sono teoricamente possibili. Questo NON è una previsione o raccomandazione.
? Scenario Positivo
Una o più approvazioni FDA in Q4 2025 / H1 2026; revenue HOPE scala; nessuna diluizione significativa.
? Scenario Neutro
FDA richiede dati aggiuntivi; approvazioni ritardate; raccolta capitale con diluizione; operazioni continuano.
? Scenario Negativo
FDA emette CRL su tutte le submission; diluizione significativa o problemi di going concern.
7. Fonti Ufficiali e Link SEC
SEC Filing
Comunicati Stampa Ufficiali
Risorse Aziendali
Altri contenuti su NRXP su Merlintrader trading Blog: NRXP – Approfondimento 1 | NRXP – Approfondimento 2 | NRXP – Analisi precedente
Scanner for active traders
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.
Start free – then use SAVE10
No credit card required to start. Apply SAVE10 when upgrading.
Recommended platform
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.
Get 1 Month Free ➔
Multi-broker workflow + customizable layouts in one platform.
Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site
Find out how I use AI on Merlintrader: AI, retail and Merlintrader
Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.
